How it works
Our platform enables flexible scaling with single organoid precision. Coupled with state-of-the art analytical technologies, BrainZell’s organoid platform is especially suitable for drug discovery research, target identification, phenotypic screening, lead optimization, neurosafety and translational research.
Our platform is designed to handle large volumes of experiments simultaneously, drastically reducing turnaround times and accelerating the path to actionable results.
Our models offer possibility for microglia co-culture, enabling the discovery of the neuroimmune aspects of disease progression and treatment response.
Customized hiPSCs Sourcing
Choosing what works best for a specific application
a diverse range of genetic backgrounds from established biobanks.
collaborating with clinical partners to obtain patient-specific cells.
iPSC lines provided by collaborating partners.
Assays
Our platform enables treatments ranging from single exposure to long term and repeated exposures.
Tests per week
Organoids